These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 39186268)

  • 1. Hepatitis C Virus Reinfection Among People Who Inject Drugs: Long-Term Follow-Up of the HERO Study.
    Litwin AH; Tsui JI; Heo M; Mehta SH; Taylor LE; Lum PJ; Feinberg J; Kim AY; Norton BL; Pericot-Valverde I; Arnsten J; Meissner P; Karasz A; McKee MD; Ward JW; Johnson N; Agyemang L; Stein ES; Thomas A; Borsuk C; Blalock KL; Wilkinson S; Wagner K; Carty J; Murray-Krezan C; Anderson J; Jacobsohn V; Luetkemeyer AF; Falade-Nwulia O; Groome M; Davies S; Costello K; Page K;
    JAMA Netw Open; 2024 Aug; 7(8):e2430024. PubMed ID: 39186268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
    Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J
    J Hepatol; 2020 Apr; 72(4):643-657. PubMed ID: 31785345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units.
    Valencia J; Alvaro-Meca A; Troya J; Cuevas G; Gutiérrez J; Morro A; Alvarez J; Pulido L; Cañamares I; Escobar I; Moreno S; Ryan P
    Int J Drug Policy; 2019 Oct; 72():181-188. PubMed ID: 31253391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
    Akiyama MJ; Lipsey D; Heo M; Agyemang L; Norton BL; Hidalgo J; Lora K; Litwin AH
    Clin Infect Dis; 2020 Jun; 70(12):2695-2702. PubMed ID: 31346609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
    Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
    J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
    Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs.
    Weir A; McLeod A; Innes H; Valerio H; Aspinall EJ; Goldberg DJ; Barclay ST; Dillon JF; Fox R; Fraser A; Hayes PC; Kennedy N; Mills PR; Stanley AJ; Aitken C; Gunson R; Templeton K; Hunt A; McIntyre P; Hutchinson SJ
    Drug Alcohol Depend; 2016 Aug; 165():53-60. PubMed ID: 27268294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
    Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
    J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study.
    Heo M; Norton BL; Pericot-Valverde I; Mehta SH; Tsui JI; Taylor LE; Lum PJ; Feinberg J; Kim AY; Arnsten JH; Sprecht-Walsh S; Page K; Murray-Krezan C; Anderson J; Litwin AH;
    J Hepatol; 2024 May; 80(5):702-713. PubMed ID: 38242324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada.
    Selfridge M; Cunningham EB; Barnett T; Drost A; Gray-Schleihauf C; Guarasci K; Lundgren K; Milne R; Grebely J; Fraser C
    Int J Drug Policy; 2021 Oct; 96():103418. PubMed ID: 34538704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
    Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
    Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway.
    Midgard H; Ulstein K; Backe Ø; Foshaug T; Sørli H; Vennesland K; Nilssen D; Dahl EH; Finbråten AK; Wüsthoff L; Dalgard O
    Int J Drug Policy; 2021 Oct; 96():103165. PubMed ID: 33642182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virologic Response and Reinfection Following HCV Treatment among Hospitalized People Who Inject Drugs: Follow-Up Data from the OPPORTUNI-C Trial.
    Malme KB; Stene-Johansen K; Klundby I; Backe Ø; Foshaug T; Greve MH; Pihl CM; Finbråten AK; Dalgard O; Midgard H
    Viruses; 2024 May; 16(6):. PubMed ID: 38932151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression.
    Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua NZ; Fierer DS; Chromy D; Rockstroh JK; Martin TCS; Ingiliz P; Hung CC; Dore GJ; Martinello M; Matthews GV
    Lancet HIV; 2022 Jun; 9(6):e414-e427. PubMed ID: 35659336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
    Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T
    Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C virus infection in Vancouver, Canada.
    Holeksa J; Magel T; Alimohammadi A; Thiam A; Yung R; Chu L; Truong D; Conway B
    Int J Drug Policy; 2019 Oct; 72():177-180. PubMed ID: 31176594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reinfection incidence and risk among people treated for recent hepatitis C virus infection.
    Martinello M; Carson JM; Van Der Valk M; Rockstroh JK; Ingiliz P; Hellard M; Nelson M; Lutz T; Bhagani S; Kim AY; Hull M; Cordes C; Moon J; Feld JJ; Gane E; Rauch A; Bruneau J; Tu E; Applegate T; Grebely J; Dore GJ; Matthews GV;
    AIDS; 2023 Oct; 37(12):1883-1890. PubMed ID: 37467042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland.
    Caven M; Baiano CX; Robinson EM; Stephens B; Macpherson I; Dillon JF
    J Viral Hepat; 2021 Dec; 28(12):1744-1750. PubMed ID: 34525228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
    Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ;
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):153-161. PubMed ID: 29310928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
    Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
    AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.